Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

685 - Retrospective analysis of cardiovascular diseases in chemotherapies for advanced solid tumor patients in a single institution


20 Dec 2015


Poster presentation 2


Tsuyoshi Shirakawa


Annals of Oncology (2015) 26 (suppl_9): 156-160. 10.1093/annonc/mdv535


T. Shirakawa1, M. Nakano2, K. Nio2, S. Tamura3, H. Kumagai4, M. Komoda4, K. Uchino4, S. Arita2, H. Ariyama2, Y. Shibata5, H. Kusaba2, K. Akashi2, E. Baba6

Author affiliations

  • 1 Oncology, Miyazaki Prefectural Miyazaki Hospital, 880-8510 - Miyazaki/JP
  • 2 Medicine And Biosystemic Science, Kyushu University Hospital, Fukuoka/JP
  • 3 Internal Medicine, Kyushu University Beppu Hospital, Oita/JP
  • 4 Medical Oncology, National Kyushu Cancer Center, Fukuoka/JP
  • 5 Medical Oncology, Wajiro Hospital, Fukuoka/JP
  • 6 Comprehensive Clinical Oncology, Kyushu University Hospital, 812-8582 - Fukuoka/JP


Abstract 685


Appropriate management of cardiovascular diseases (CVDs) in association with chemotherapy for solid tumors is important for performing safety chemotherapy. However, predicting the onset and progression of CVDs related with chemotherapy have not been well established.


We conducted retrospective analysis for advanced or recurrent solid tumor patients who were admitted in our hospital and received chemotherapies. Surveyed items were as follows; patients characteristics, chemotherapy regimens, adverse events, CVDs prior to chemotherapy, diagnosis and therapies for CVDs in association with chemotherapy.


During the period from April 2006 to March 2012, 394 patients who were treated with chemotherapy for solid tumors were examined. Cardiac arrhythmia, left ventricular dysfunction (LVD), cardiac ischemia/infarction (IHD), hypertension (HT), hypotension, arterial thrombosis and venous thrombosis were seen in 23 (5.8%), 15 (3.8%), 2 (0.5%), 24 (6.1%), 5 (1.3%), 5 (1.3%), and 14 (3.5%) cases, respectively. HT (15.7%) and arterial or venous thrombosis (5.7%) were frequent in patients who received bevacizumab-containing chemotherapy. Four cases with left ventricular dysfunction experienced decrease of ejection fraction (EF) and early filling/atrial filling (E/A) in chemotherapy, and the decrease of E/A tended to be seen before that of EF. Ninety (62.1%) among 146 cases whose D-dimers (DD) were measured prior to chemotherapy showed the elevation of DD, and the further increase of DD was seen when venous thrombosis occurred. Relative risks of the disease progression of HT and IHD due to chemotherapy for past histories of them were 1.4 and 2.6, respectively.


The decrease of E/A and the increase of DD were suggested to be useful for early diagnosis of the respective onsets of LVD and venous thrombosis related with chemotherapy. Patients with previous HT or IHD have a high risk of the disease progression after the induction of chemotherapy. Accumulation of clinical studies about CVDs related with chemotherapy is needed for performing chemotherapy safely.

Clinical trial identification

This is a retrospective trial.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings